^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ERG344

    i
    Other names: ERG344
    Associations

    News

    Trials
    Company:
    Ergon Pharma
    Drug class:
    IRG1 inhibitor
    Associations

    News

    Trials
    almost5years
    [VIRTUAL] ERG344: A novel IRG1 inhibitor for the treatment of colon cancer (AACR 2021)
    Seven days after tumor inoculation, mice treated with ERG344 showed reduced tumor growth in the peritoneal cavity, which led to increased survival probability of the animals. The studies collectively suggest that IRG1 is a novel target for the treatment of primary and metastatic tumor growth in colorectal cancer and highlight the therapeutic potential of ERG344.
    PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1)
    |
    CD8 expression
    |
    ERG344